Literature DB >> 21357392

Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog.

Gerard A Lutty1, D Scott McLeod, Imran Bhutto, Stanley J Wiegand.   

Abstract

Purpose. To evaluate the effects of a vascular endothelial growth factor trap (VEGF Trap) on retinal vascular development and pathologic neovascularization (NV) in the canine model of oxygen-induced retinopathy (OIR). Methods. Newborn dogs (postnatal day [P]1) were exposed to 100% O(2) and then returned to room air on P5. VEGF Trap (5, 25, or 250 μg) was injected intravitreally in one eye and human FC (hFc) injected in the fellow eye of air control and oxygen-treated dogs on P8. The retinal vasculature and NV were evaluated on P21. Other oxygen-exposed animals received 5 μg of VEGF Trap or hFc on P22 after confirmation of retinopathy of prematurity (ROP)-like pathology and were evaluated at P45. Results. In air controls, both the vascularized area of the retina and the density of superficial capillaries were reduced in 250 or 25 μg VEGF Trap-injected eyes, and deep capillaries were absent. Eyes that received the 5 μg dose were indistinguishable from controls. In oxygen-treated animals, all eyes injected with VEGF Trap exhibited markedly less intravitreal NV than that of hFc-injected fellow eyes, irrespective of dose. Retinal vascular area in OIR animals was significantly reduced in eyes injected with 250 or 25 μg of VEGF Trap, but the 5 μg dose did not inhibit retinal revascularization. Eyes with existing NV that received 5 μg VEGF Trap at P22 exhibited substantial resolution of OIR pathology at P45. Conclusions. The VEGF Trap inhibited the formation of NV, but higher doses also inhibited revascularization of retina when injected at P8. In contrast, the lowest dose tested effectively blocked NV and caused regression of existing NV, without appreciably affecting vasculogenesis or retinal revascularization. These findings suggest that dose selection is an important variable when considering the use of VEGF-targeting agents for the treatment of ROP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357392      PMCID: PMC3175979          DOI: 10.1167/iovs.10-6798

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  48 in total

Review 1.  Development and pathology of the hyaloid, choroidal and retinal vasculature.

Authors:  Magali Saint-Geniez; Patricia A D'Amore
Journal:  Int J Dev Biol       Date:  2004       Impact factor: 2.203

2.  The initial fetal human retinal vasculature develops by vasculogenesis.

Authors:  D Scott McLeod; Takuya Hasegawa; Tarl Prow; Carol Merges; Gerard Lutty
Journal:  Dev Dyn       Date:  2006-12       Impact factor: 3.780

3.  Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.

Authors:  António Travassos; Susana Teixeira; Pinto Ferreira; Isaura Regadas; Ana Sofia Travassos; Florindo Esteves Esperancinha; Isabel Prieto; Grapa Pires; Robert van Velze; A Valido; Maria do Céu Machado
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2007 May-Jun

Review 4.  VEGF as a key mediator of angiogenesis in cancer.

Authors:  Peter Carmeliet
Journal:  Oncology       Date:  2005-11-21       Impact factor: 2.935

5.  Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).

Authors:  Gerard A Lutty; Tailoi Chan-Ling; Dale L Phelps; Anthony P Adamis; Kenneth I Berns; Candy K Chan; Cynthia H Cole; Patricia A D'Amore; Arup Das; Wen-Tao Deng; Velma Dobson; John T Flynn; Martin Friedlander; Anne Fulton; William V Good; Maria B Grant; Ronald Hansen; William W Hauswirth; Robert J Hardy; David R Hinton; Suzanne Hughes; D Scott McLeod; Earl A Palmer; Arnall Patz; John S Penn; Brian J Raisler; Michael X Repka; Magali Saint-Geniez; Lynn C Shaw; David T Shima; Bradley T Smith; Lois E H Smith; Sjakon G Tahija; William Tasman; Michael T Trese
Journal:  Mol Vis       Date:  2006-05-23       Impact factor: 2.367

6.  Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy.

Authors:  M K Mathews; C Merges; D S McLeod; G A Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-12       Impact factor: 4.799

7.  Clinical and histopathologic features of canine oxygen-induced proliferative retinopathy.

Authors:  D S McLeod; S A D'Anna; G A Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-09       Impact factor: 4.799

8.  Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.

Authors:  E A Pierce; E D Foley; L E Smith
Journal:  Arch Ophthalmol       Date:  1996-10

9.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Authors:  Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 10.  The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.

Authors:  David I R Holmes; Ian Zachary
Journal:  Genome Biol       Date:  2005-02-01       Impact factor: 13.583

View more
  31 in total

1.  Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.

Authors:  Andreas Stahl; Tim U Krohne; Nicole Eter; Isabel Oberacher-Velten; Rainer Guthoff; Synke Meltendorf; Oliver Ehrt; Sabine Aisenbrey; Johann Roider; Heinrich Gerding; Claudia Jandeck; Lois E H Smith; Johanna M Walz
Journal:  JAMA Pediatr       Date:  2018-03-01       Impact factor: 16.193

Review 2.  Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?

Authors:  Andreas Stahl; Ann Hellstrom; Lois E H Smith
Journal:  Neonatology       Date:  2014-10-05       Impact factor: 4.035

3.  Adenosine A1 Receptors Selectively Modulate Oxygen-Induced Retinopathy at the Hyperoxic and Hypoxic Phases by Distinct Cellular Mechanisms.

Authors:  Shuya Zhang; Haiyan Li; Bo Li; Dingjuan Zhong; Xuejiao Gu; Lingyun Tang; Yanyan Wang; Cun Wang; Rong Zhou; Yan Li; Yan He; Mozi Chen; Yuqing Huo; Xiao-Ling Liu; Jiang-Fan Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

4.  Ischemia-reperfusion injury induces occludin phosphorylation/ubiquitination and retinal vascular permeability in a VEGFR-2-dependent manner.

Authors:  Arivalagan Muthusamy; Cheng-Mao Lin; Sumathi Shanmugam; Heather M Lindner; Steven F Abcouwer; David A Antonetti
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-08       Impact factor: 6.200

Review 5.  Retinopathy of prematurity: Past, present and future.

Authors:  Parag K Shah; Vishma Prabhu; Smita S Karandikar; Ratnesh Ranjan; Venkatapathy Narendran; Narendran Kalpana
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 6.  Pathophysiology and mechanisms of severe retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Ophthalmology       Date:  2014-10-14       Impact factor: 12.079

7.  Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity.

Authors:  Shwetha Mangalesh; Isaac D Bleicher; Xi Chen; Christian Viehland; Francesco LaRocca; Joseph A Izatt; Sharon F Freedman; M Elizabeth Hartnett; Cynthia A Toth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-02-21       Impact factor: 3.117

8.  Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.

Authors:  Fen Tang; Michelle E LeBlanc; Weiwen Wang; Dan Liang; Ping Chen; Tsung-Han Chou; Hong Tian; Wei Li
Journal:  Angiogenesis       Date:  2019-01-14       Impact factor: 9.596

Review 9.  Secretogranin III: a diabetic retinopathy-selective angiogenic factor.

Authors:  Wei Li; Keith A Webster; Michelle E LeBlanc; Hong Tian
Journal:  Cell Mol Life Sci       Date:  2017-08-30       Impact factor: 9.261

10.  Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity.

Authors:  Manabu McCloskey; Haibo Wang; Yanchao Jiang; George Wesley Smith; Jeremy Strange; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-21       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.